市場調查報告書

全球醫療奈米技術市場:成長,趨勢,及預測(2017年∼2022年)

Healthcare Nanotechnology (Nanomedicine) Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 391463
出版日期 內容資訊 英文 116 Pages
商品交期: 2-3個工作天內
價格
全球醫療奈米技術市場:成長,趨勢,及預測(2017年∼2022年) Healthcare Nanotechnology (Nanomedicine) Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 116 Pages
簡介

高精度可靠性高的醫療奈米技術,今後是值得期待成長的領域之一。2013年臨床腫瘤獨佔市場,不過,在調查期間中心血管領域的奈米醫療急速成長。

本報告提供全球醫療奈米技術市場相關調查,市場概要,各應用領域、疾病、地區的市場趨勢,市場規模的變化與預測,市場成長、阻礙因素以及市場機會、課題分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 市場定義
  • 基本單位
  • 基本貨幣
  • 調查對象期間及預測
  • 一般調查的前提條件
  • 報告的說明

第2章 調查方法

  • 簡介
  • 分析方法
  • 調查的時間軸
  • 調查的階段
    • 2次調查
    • 討論指南
    • 市場工程&計量經濟學模式

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要與產業趨勢

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 市場成長要素
    • 研究資金的增加
    • 心血管疾病的盛行率的上升
    • 老年人口的增加
    • 奈米醫療的興趣
    • 龐大的未滿足需求
    • 新加入企業的增加競爭激烈化
  • 市場阻礙因素
    • 奈米醫療為基礎的醫療設備的成本
    • 核准流程的長度
  • 市場機會
    • 癌症治療的應用擴大
  • 主要課題
    • 毒性

第7章 全球醫療奈米技術市場:市場區隔

  • 各應用領域
    • 藥物輸送
    • 醫藥品
    • 生物材料
    • 活性植入
    • 體外診斷
    • 體內成像
  • 各疾病
    • 神經系統疾病
    • 心血管疾病
    • 腫瘤
    • 發炎
    • 感染疾病
    • 其他

第8章 全球醫療奈米技術市場:各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙、葡萄牙
    • 斯堪地那維亞各國
    • 荷比盧三國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲、紐西蘭
    • 韓國
    • 其他
  • 中東、非洲
    • 波灣合作理事會(GCC)
    • 南非
    • 其他
  • 中南美
    • 巴西
    • 阿根廷
    • 其他

第9章 競爭情形

  • M&A分析
  • 新產品的銷售
  • 協定,合作,夥伴關係

第10章 企業簡介

  • Abbott Laboratories
  • CombiMatrix Corporation
  • GE Healthcare
  • Sigma-Tau Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Mallinckrodt PLC
  • Merck & Company, Inc.
  • Nanosphere, Inc.
  • Pfizer, Inc.
  • Celgene Corporation
  • Teva Pharmaceutical Industries Ltd.
  • UCB (Union chimique belge) SA
  • 其他的企業

第11章 分析師的投資機會預測

第12章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 52957

Market Overview

Nanoscale technology is widely used in medical devices and medicine where manipulations are made at the molecular level, taking advantage of the novel properties of a material. The primary demand of this field in medicine is in making improvements in the delivery of treatments and healthcare outcomes. Nanomedicine refers to the usage of nanoscale healthcare technology in pharmaceutical applications to make medically useful products.

Nanomedicine is a promising mode of cancer treatment. This growing field of medical research can be used to discover a better-personalized treatment for a range of diseases, including cancers. With the advantage of the properties of matter at the nanoscale, nanomedicine promises to develop innovative drugs with greater efficacy and lesser side effects than standard therapies. The need for technological advancements to enhance disease diagnosis, treatment, and prevention is the major driver for the nanomedicine market. In the case of cancers, nanomedicine offers promising changes from the current methods of diagnosing and treating cancer. Translation of nano-based cancer therapies and diagnostics has witnessed significant progress and several new developments are in the pipeline. Along with these, multiple other factors are also driving the growth of this market in the healthcare industry.

Scope of the Report

As per the scope of the report, the healthcare nanotechnology (nanomedicine) market includes products that are nanoformulations of the existing drugs or new drugs or are nanobiomaterials. The market is segmented by its application in the medical field, as drug delivery, biomaterials, active implants, diagnostic imaging, tissue regeneration, and other applications. The market is also segmented by its use in the treatment of diseases, like cardiovascular diseases, oncological diseases, neurological diseases, orthopedic diseases, infectious diseases, and other diseases.

Key Market Trends

The Growth of Nanomedicine is Expected to Provide High Opportunities for the Treatment of Neurological Diseases, Over the Forecast Period

A large number of brain disorders with neurological and psychological conditions result in short-term and long-term disabilities. Recent years observed a significant number of research studies being published on methods for the synthesis of nanoparticle-encapsulated drugs within in vivo and in vitro studies. The insufficient absorbance of oral drugs administered for a range of neurological conditions, such as Alzheimer's disease, Parkinson disease, tumor, neuro-AIDS, among others, opens up the necessity of nanomedicine with stem cell therapy. Some of the registered nanoparticles for the complex CNS treatment are a gold nanoparticle, lipid nanoparticle, and chitosan nanoparticles.

Other than neurological diseases, research-based progress was found in the treatment of cancers, with the scientific communities identifying new metabolic pathways to find better drug combination using nanomedicine.

North America is Expected to Hold the Largest Share in the Market

In the United States, several companies are closely observing the developments in nanostructured materials across various applications in the healthcare industry, including medical devices, to improve efficiency and efficacy. In the United States, the National Nanotechnology Initiative (NNI), which was initiated in 2000, is among the supreme bodies that manage all nanotechnology-related activities. Under the NNI, several agencies are working in collaboration with companies and universities. For instance, nano-manufacturing in Small Business Innovation Research (SBIR) programs were developed for both commercial and public use. Companies are targeting the treatment of several cancer types and infectious diseases through immunotherapy, where nanoemulsion vaccines and drugs play a significant role. In the United States, one of the major challenges associated with nanotechnology is the ability to integrate nanoscale materials into new devices and systems, along with an application of novel properties at the nano-level. Thus, most of the companies are investing in R&D. Nanotechnology is likely to play a significant role in the delivery of drugs. In the recent strategic plan presented by the NNI in 2016, several programs were identified to further advance the research and development programs, over the forecast period.

Competitive Landscape

The major market players are focusing on technological advancements and improvements in drug bioavailability and drug administration. Some of the major players in the market are Sanofi SA, Pfizer Inc., Celgene Corporation, Luminex Corporation, and Taiwan Liposome Company Ltd.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Cancer and Genetic and Cardiovascular Diseases
    • 4.2.2 Increasing Advancements in Nanoscale Technologies for Diagnostic Procedures
    • 4.2.3 Growing Preference for Personalized Medicines
  • 4.3 Market Restraints
    • 4.3.1 High Cost
    • 4.3.2 Stringent Regulations for Commercial Introduction
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Application
    • 5.1.1 Drug Delivery
    • 5.1.2 Biomaterials
    • 5.1.3 Active Implants
    • 5.1.4 Diagnostic Imaging
    • 5.1.5 Tissue Regeneration
    • 5.1.6 Other Applications
  • 5.2 By Disease
    • 5.2.1 Cardiovascular Diseases
    • 5.2.2 Oncological Diseases
    • 5.2.3 Neurological Diseases
    • 5.2.4 Orthopedic Diseases
    • 5.2.5 Infectious Diseases
    • 5.2.6 Other Diseases
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 France
      • 5.3.2.2 Germany
      • 5.3.2.3 UK
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Sanofi SA
    • 6.1.2 Celegene Corporation
    • 6.1.3 CytImmune Sciences Inc.
    • 6.1.4 Johnson & Johnson
    • 6.1.5 Luminex Corporation
    • 6.1.6 Merck & Co. Inc.
    • 6.1.7 Nanobiotix
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Starpharma Holdings Limited
    • 6.1.10 Taiwan Liposome Company Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS